This was in contrast to a report of an in vivo xenograft model of breast cancer where an Fc- activity deficient form of trastuzumab was able to fully block Her2 and downstream ERK and AKT phosphorylation despite only partial inhibition of tumor growth.46 The gene discussed is ERBB2; the disease is breast cancer.